Vericiguat
drugOn this page
Also known as BAY 1021189BAY-1021189MK-1242Verquvo
Summary
Vericiguat (CHEMBL4066936) is an approved small-molecule soluble guanylate cyclase activator (ATC C01DX22); indicated across 3 conditions including heart failure and cardiovascular disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: C01DX22
- Indications: 3 conditions
- Clinical trials: 28
- Chemistry: 426.4 Da · C19H16F2N8O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4066936 |
| Name | Vericiguat |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 54674461 |
| ChEBI | CHEBI:142432 |
| ATC | C01DX22 |
| Molecular formula | C19H16F2N8O2 |
| Molecular weight | 426.4 |
| InChIKey | QZFHIXARHDBPBY-UHFFFAOYSA-N |
SMILES: COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N
IUPAC name: methyl N-[4,6-diamino-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[5,4-b]pyridin-3-yl]pyrimidin-5-yl]carbamate
ChEBI definition: A pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure.
Pharmacological roles (ChEBI): soluble guanylate cyclase activator, vasodilator agent, antihypertensive agent.
Also known as: BAY 1021189, BAY-1021189, MK-1242, Vericiguat, Verquvo, VERICIGUAT
Patent coverage: 226 distinct patent families (595 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 445 (75%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| Guanylyl cyclase, α1β1 | Activation | ||||
| Guanylyl cyclase, α2β1 | Activation |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| heart failure | 4 | MONDO:0005252 | EFO:0003144 |
| cardiovascular disorder | 4 | MONDO:0004995 | EFO:0000319 |
| coronary artery disorder | 1 | MONDO:0005010 | EFO:0001645 |
Clinical trials
Total trials: 28.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 9 |
| PHASE1 | 7 |
| PHASE4 | 6 |
| Not specified | 3 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05704478 | PHASE4 | ACTIVE_NOT_RECRUITING | Impact of Vericiguat on Hemodynamics of Heart Failure |
| NCT05812755 | PHASE4 | RECRUITING | SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery |
| NCT06671990 | PHASE4 | NOT_YET_RECRUITING | The CardioMEMS Vericiguat Heart Failure Trial |
| NCT06812546 | PHASE4 | NOT_YET_RECRUITING | Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction |
| NCT07405944 | PHASE4 | RECRUITING | Vericiguat and Reverse Remodeling Indices in Heart Failure |
| NCT05420012 | PHASE4 | COMPLETED | The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation |
| NCT05714085 | PHASE2/PHASE3 | RECRUITING | Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) |
| NCT02861534 | PHASE3 | COMPLETED | A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) |
| NCT05093933 | PHASE3 | COMPLETED | A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) |
| NCT05697640 | PHASE2 | ACTIVE_NOT_RECRUITING | Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome |
| NCT05806138 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction |
| NCT06320951 | PHASE2 | NOT_YET_RECRUITING | VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway |
| NCT06415227 | PHASE2 | NOT_YET_RECRUITING | The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris |
| NCT06601465 | PHASE2 | RECRUITING | COgnitioN With VERiciGuat Evaluation in Heart Failure |
| NCT01951625 | PHASE2 | COMPLETED | Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED) |
| NCT01951638 | PHASE2 | COMPLETED | Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED) |
| NCT05711719 | PHASE2 | COMPLETED | Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction |
| NCT06195930 | PHASE2 | COMPLETED | A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction |
| NCT07444398 | PHASE1 | RECRUITING | Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial |
| NCT02617550 | PHASE1 | COMPLETED | Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients |
| NCT03255512 | PHASE1 | COMPLETED | Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients |
| NCT03504982 | PHASE1 | COMPLETED | Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat |
| NCT04722484 | PHASE1 | COMPLETED | A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants |
| NCT04722562 | PHASE1 | COMPLETED | A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants |
| NCT05086952 | PHASE1 | COMPLETED | A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately |
| NCT06239974 | Not specified | RECRUITING | Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM) |
| NCT07047547 | Not specified | RECRUITING | A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure |
| NCT07594509 | Not specified | NOT_YET_RECRUITING | Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: heart failure, cardiovascular disorder